SEQUENT

Sequent Scientific Share Price

₹143.21 -0.89 (-0.62%)

02 May, 2025 23:01

SIP TrendupStart SIP in SEQUENT

Start SIP

Performance

  • Low
  • ₹142
  • High
  • ₹146
  • 52 Week Low
  • ₹92
  • 52 Week High
  • ₹241
  • Open Price₹144
  • Previous Close₹144
  • Volume396,460

Investment Returns

  • Over 1 Month + 5.45%
  • Over 3 Month -12.74%
  • Over 6 Month -25.2%
  • Over 1 Year + 15.82%
SIP Lightning

Smart Investing Starts Here Start SIP with Sequent Scientific for Steady Growth!

Invest Now

Sequent Scientific Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 194.6
  • PEG Ratio
  • 1.7
  • Market Cap Cr
  • 3,585
  • P/B Ratio
  • 5.3
  • Average True Range
  • 7.13
  • EPS
  • 0.51
  • Dividend Yield
  • 0
  • MACD Signal
  • 0.52
  • RSI
  • 48.75
  • MFI
  • 63.52

Sequent Scientific Financials

Sequent Scientific Technicals

EMA & SMA

Current Price
₹143.21
-0.89 (-0.62%)
pointer
  • stock-down_img
  • Bearish Moving Average 14
  • stock-up_img
  • Bullish Moving Average 2
  • 20 Day
  • ₹144.42
  • 50 Day
  • ₹147.69
  • 100 Day
  • ₹155.47
  • 200 Day
  • ₹156.69

Resistance and Support

143.69 Pivot Speed
  • R3 150.35
  • R2 148.29
  • R1 145.75
  • S1 141.15
  • S2 139.09
  • S3 136.55

What's your outlook on Sequent Scientific?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Sequent Scientific Ltd. is a leading animal health company in India, specializing in the manufacturing of veterinary pharmaceuticals, including APIs and formulations. It serves global markets with a strong focus on quality, compliance, and innovation.

Sequent Scientific has an operating revenue of Rs. 1,510.87 Cr. on a trailing 12-month basis. An annual revenue de-growth of -3% needs improvement, Pre-tax margin of -4% needs improvement, ROE of -5% is poor and needs improvement. The company has a reasonable debt to equity of 22%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 200DMA and close to its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 28 which is a POOR score indicating inconsistency in earnings, a RS Rating of 59 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C which is evident from recent supply seen, Group Rank of 75 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Sequent Scientific Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-02-11 Quarterly Results
2024-11-13 Quarterly Results
2024-08-14 Quarterly Results
2024-05-15 Audited Results & Final Dividend
2024-02-13 Quarterly Results
Date Purpose Remarks
2021-09-10 FINAL Rs.0.50 per share(25%)Final Dividend
View More

Sequent Scientific F&O

Sequent Scientific Shareholding Pattern

52.61%
10.22%
6.05%
23.43%
7.69%

About Sequent Scientific

  • NSE Symbol
  • SEQUENT
  • BSE Symbol
  • 512529
  • Managing Director & CEO
  • Mr. Rajaram Narayanan
  • ISIN
  • INE807F01027

Similar Stocks to Sequent Scientific

Sequent Scientific FAQs

Sequent Scientific share price is ₹143 As on 02 May, 2025 | 22:47

The Market Cap of Sequent Scientific is ₹3584.6 Cr As on 02 May, 2025 | 22:47

The P/E ratio of Sequent Scientific is 194.6 As on 02 May, 2025 | 22:47

The PB ratio of Sequent Scientific is 5.3 As on 02 May, 2025 | 22:47

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23